SE445296B - Sett att i en fysiologisk losning framstella en suspension av med metotrexat belastade blodceller - Google Patents
Sett att i en fysiologisk losning framstella en suspension av med metotrexat belastade blodcellerInfo
- Publication number
- SE445296B SE445296B SE7713946A SE7713946A SE445296B SE 445296 B SE445296 B SE 445296B SE 7713946 A SE7713946 A SE 7713946A SE 7713946 A SE7713946 A SE 7713946A SE 445296 B SE445296 B SE 445296B
- Authority
- SE
- Sweden
- Prior art keywords
- cells
- solution
- loaded
- physiological solution
- loaded cells
- Prior art date
Links
- 239000000725 suspension Substances 0.000 title claims description 19
- 210000000601 blood cell Anatomy 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims description 125
- 239000000243 solution Substances 0.000 claims description 71
- 238000000034 method Methods 0.000 claims description 23
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 22
- 229960000485 methotrexate Drugs 0.000 claims description 22
- 210000003743 erythrocyte Anatomy 0.000 claims description 18
- 239000013543 active substance Substances 0.000 claims description 17
- 210000004185 liver Anatomy 0.000 claims description 17
- 210000000170 cell membrane Anatomy 0.000 claims description 13
- 230000005684 electric field Effects 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 210000000952 spleen Anatomy 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 230000003204 osmotic effect Effects 0.000 claims description 7
- 239000002502 liposome Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 230000004060 metabolic process Effects 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 210000001772 blood platelet Anatomy 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 230000008929 regeneration Effects 0.000 claims description 2
- 238000011069 regeneration method Methods 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 239000012528 membrane Substances 0.000 description 17
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 14
- 230000035699 permeability Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 235000011164 potassium chloride Nutrition 0.000 description 7
- 239000001103 potassium chloride Substances 0.000 description 7
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 6
- 229910052722 tritium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000008151 electrolyte solution Substances 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/108331—Preservative, buffer, anticoagulant or diluent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2656746A DE2656746C2 (de) | 1976-12-15 | 1976-12-15 | Verwendung von beladenen Erythrozyten |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7713946L SE7713946L (sv) | 1978-06-16 |
| SE445296B true SE445296B (sv) | 1986-06-16 |
Family
ID=5995573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7713946A SE445296B (sv) | 1976-12-15 | 1977-12-08 | Sett att i en fysiologisk losning framstella en suspension av med metotrexat belastade blodceller |
Country Status (8)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2655801C2 (de) * | 1976-12-09 | 1986-06-26 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Injizierbare Suspension von Membranvesikeln aus Erythrozyten und Verfahren zur Herstellung der Suspension |
| US4403038A (en) * | 1979-04-11 | 1983-09-06 | Toshio Asakura | Buffered serum substitute for blood oxygen analyzer |
| US4358394A (en) * | 1979-05-07 | 1982-11-09 | Coulter Electronics, Inc. | Process for preparing whole blood reference controls having long term stability |
| US4489162A (en) * | 1981-12-21 | 1984-12-18 | American Hospital Supply Corporation | Fresh blood (unfixed) hematology control |
| FR2529463B1 (fr) * | 1982-07-05 | 1986-01-10 | Centre Nat Rech Scient | Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus |
| US4478824A (en) * | 1983-08-08 | 1984-10-23 | Franco Robert S | Method for altering red blood cell function and survival |
| WO1987006851A1 (en) * | 1986-05-09 | 1987-11-19 | Electropore, Inc. | Apparatus and method for vesicle poration, loading and fusion |
| US4906576A (en) * | 1986-05-09 | 1990-03-06 | Electropore, Inc. | High speed, high power apparatus for vesicle prealignment, poration, loading and fusion in uniform electric fields and method therefor |
| US4923814A (en) * | 1986-05-09 | 1990-05-08 | Electropore, Inc. | High speed, high power apparatus for vesicle prealignment, poration, loading and fusion in uniform electric fields and method therefor |
| US4931276A (en) * | 1987-10-30 | 1990-06-05 | Franco Robert S | Method for introducing desired agents into red blood cells |
| CA1327174C (en) * | 1988-10-05 | 1994-02-22 | Youssef Mouneimne | Electro-insertion of proteins into animal cell membranes |
| US5236835A (en) * | 1988-10-05 | 1993-08-17 | Hapgood, C.V. | Electro insertion of proteins into red cell membranes |
| US5443813A (en) * | 1991-06-06 | 1995-08-22 | Associated Universities, Inc. | Loading and conjugating cavity biostructures |
| US5173158A (en) * | 1991-07-22 | 1992-12-22 | Schmukler Robert E | Apparatus and methods for electroporation and electrofusion |
| WO1993018397A1 (en) * | 1992-03-02 | 1993-09-16 | Streck Laboratories, Inc. | Reference control for use with manual and flow cytometric reticulocyte counting devices |
| DE69732225T2 (de) * | 1997-05-05 | 2005-06-23 | Dideco S.R.L., Mirandola | Verfahren zur Verkapselung von biologisch aktiven Stoffen in Erythrocyten und Gerät dafür |
| CA2540695A1 (en) * | 2003-06-24 | 2004-12-29 | Baxter International Inc. | Specific delivery of drugs to the brain |
| US8986736B2 (en) * | 2003-06-24 | 2015-03-24 | Baxter International Inc. | Method for delivering particulate drugs to tissues |
| KR20060135729A (ko) * | 2004-01-29 | 2006-12-29 | 백스터 인터내셔널 인코포레이티드 | 중추신경계 전달 증가를 위한 항레트로바이러스제의나노현탁액 |
| BRPI0510271A (pt) * | 2004-06-15 | 2007-10-30 | Baxter Int | aplicações ex-vivo agentes terapêuticos microparticulados |
| DE102004054536A1 (de) * | 2004-11-06 | 2006-05-11 | Capsulution Nanoscience Ag | Multimodal veränderte Zellen als zellulare Darreichungsformen für aktive Substanzen und als diagnostische Zellpartikel |
| RU2496482C2 (ru) | 2008-03-05 | 2013-10-27 | Бакстер Интернэшнл Инк. | Композиции и способы для доставки лекарственных средств |
| US10952965B2 (en) * | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3887698A (en) * | 1973-03-12 | 1975-06-03 | Univ Leland Stanford Junior | Sacs with epitopic sites on walls enclosing stable free radicals |
| DE2326224C3 (de) | 1973-05-23 | 1975-11-13 | Kernforschungsanlage Juelich Gmbh, 5170 Juelich | Verfahren zum Abtrenne», von durch chemische oder physikalisch^ Eigenschaften ausgezeichneten ionisierten Stoffen aus einer wäßrigen Lösung |
| DE2326191B2 (de) | 1973-05-23 | 1978-03-30 | Hutschenreuther Ag, 8672 Selb | Verfahren zum Herstellen eines Reliefdekors auf keramischen Erzeugnissen |
| DE2326161C2 (de) * | 1973-05-23 | 1986-07-17 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Verfahren zum Aufbau oder zum Abbau von durch chemische Eigenschaften ausgezeichneten, in einer wäßrigen Lösung enthaltenen Stoffen |
| GB1481480A (en) * | 1974-02-02 | 1977-07-27 | Kernforschungsanlage Juelich | Process and apparatus for increasing the permeability of the membrane of cells of organisms |
| DE2655801C2 (de) * | 1976-12-09 | 1986-06-26 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Injizierbare Suspension von Membranvesikeln aus Erythrozyten und Verfahren zur Herstellung der Suspension |
-
1976
- 1976-12-15 DE DE2656746A patent/DE2656746C2/de not_active Expired
-
1977
- 1977-11-11 CH CH1378877A patent/CH632928A5/de not_active IP Right Cessation
- 1977-12-08 SE SE7713946A patent/SE445296B/sv not_active IP Right Cessation
- 1977-12-13 IL IL53596A patent/IL53596A/xx unknown
- 1977-12-14 US US05/860,570 patent/US4289756A/en not_active Expired - Lifetime
- 1977-12-14 FR FR7737673A patent/FR2374045A1/fr active Granted
- 1977-12-15 JP JP14998577A patent/JPS5375385A/ja active Pending
- 1977-12-15 GB GB52188/77A patent/GB1557649A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IL53596A (en) | 1981-06-29 |
| IL53596A0 (en) | 1978-03-10 |
| GB1557649A (en) | 1979-12-12 |
| FR2374045A1 (fr) | 1978-07-13 |
| JPS5375385A (en) | 1978-07-04 |
| DE2656746C2 (de) | 1986-06-26 |
| SE7713946L (sv) | 1978-06-16 |
| US4289756A (en) | 1981-09-15 |
| CH632928A5 (de) | 1982-11-15 |
| DE2656746A1 (de) | 1978-06-29 |
| FR2374045B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1981-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE445296B (sv) | Sett att i en fysiologisk losning framstella en suspension av med metotrexat belastade blodceller | |
| SE445423B (sv) | Forfarande for framstellning av en suspension av i fysiologisk losning suspenderade och med metotrexat eller 6-fluorouracil belastade blodceller samt magnetiska substanser | |
| Ussing et al. | The Alkali Metal Ions in Biology: I. The Alkali Metal Ions in Isolated Systems and Tissues. II. The Alkali Metal Ions in the Organism | |
| US4224313A (en) | Physiological preparation containing loaded cells in suspension and an agent for counteraction of cell membrane disintegration | |
| Cooper et al. | Bile salts and cholesterol in the pathogenesis of target cells in obstructive jaundice | |
| Van Heeswijk et al. | Kinetic properties of the ATP-dependent Ca2+ pump and the Na+/Ca2+ exchange system in basolateral membranes from rat kidney cortex | |
| Bradford et al. | Depolarizing stimuli and the release of physiologically active amino acids from suspensions of mammalian synaptosomes | |
| Claret et al. | The effect of membrane cholesterol on the sodium pump in red blood cells. | |
| Puszkin et al. | Actomyosin‐like protein in brain: subcellular distribution | |
| Rudnick et al. | Equilibrium between two forms of the lac carrier protein in energized and nonenergized membrane vesicles from Escherichia coli | |
| JP2016518402A (ja) | １種以上の薬学上重要な物質が装填された赤血球の調製方法およびそのようにして得られた赤血球 | |
| Massini et al. | Ca2+ ionophores and the activation of human blood platelets: The effects of ionomycin, beauvericin, lysocellin, virginiamycin S, lasalocid-derivatives and McN 4308 | |
| Favara et al. | Familial paroxysmal rhabdomyolysis in children: A myoglobinuric syndrome | |
| Freeman | Reversible myocarditis due to chronic lead poisoning in childhood | |
| Comfurius et al. | Interaction between phosphatidylserine and the isolated cytoskeleton of human blood platelets | |
| Hillman et al. | Amino acid transport by isolated mammalian renal tubules: III. Binding of l-proline by proximal tubule membranes | |
| Chew | Effects of Yunnan Bai Yao on blood platelets: an ultrastructural study | |
| Baron | Down with plasma! Intracellular chemical pathology studied by analysis of cells of solid tissues, erythrocytes, and leukocytes | |
| Greville et al. | Observations on the fragmentation of isolated flight-muscle mitochondria from Calliphora erythrocephala (Diptera) | |
| Wu et al. | Heart sarcolemmal Ca2+ transport in endotoxin shock: I. Impairment of ATP-dependent Ca2+ transport | |
| Ortiz et al. | Sodium‐and adenosine‐triphosphate‐dependent calcium movements in membrane vesicles prepared from dog erythrocytes. | |
| KR20200094105A (ko) | 엑소좀을 추출하는 방법 및 이에 이용되는 조성물 | |
| US2290146A (en) | Composition capable of inhibiting agglutination or hemolysis in blood | |
| JANDL | Analytical review: Leaky red cells | |
| Sundharagiati et al. | A CLINICAL AND EXPERIMENTAL STUDY OF THE ERYTHRO-CYTE ULTRASTRUCTURE MEMBRANE WITH THE ELECTRON MICROSCOPE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 7713946-7 Effective date: 19880927 Format of ref document f/p: F |